SZN 1326
Alternative Names: SZN-1326Latest Information Update: 22 Jan 2024
At a glance
- Originator Surrozen
- Class Anti-inflammatories; Bispecific antibodies
- Mechanism of Action Wnt signalling pathway stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 19 Jan 2024 Discontinued - Phase-I for Inflammatory bowel diseases in USA (SC)
- 19 Jan 2024 Discontinued - Phase-I for Inflammatory bowel diseases in USA, USA (IV)
- 17 Jan 2024 Discontinued - Preclinical for Ulcerative colitis in USA (Intraperitoneal)